This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

21 Jun 2021

GSK agrees to sell its Poznań manufacturing site to Delpharm.

Poznań, Poland, Thursday 15 October 2020 –GSK and Delpharm announced today they have entered into an agreement under which Delpharm will acquire GSK’s Poznań manufacturing facility in Poland.

Poznań, Poland, Thursday 15 October 2020 –GSK and Delpharm announced today they have entered into an agreement under which Delpharm will acquire GSK’s Poznań manufacturing facility in Poland. Subject to the appropriate regulatory clearances, the transaction will see the ownership of GSK’s Poznań manufacturing site – including all facilities and around 700 manufacturing employees – transfer over to Delpharm. Delpharm will continue to manufacture, under contract, the existing GSK product line for a minimum of five years, while GSK will remain the owner and marketing authorisation holder of these products.

Delpharm, headquartered in France, is among the world’s leading contract development and manufacturing organisations. The company has been committed to delivering high quality products and development services for more than 30 years, now serving 120 markets.

Commenting on the sale, Kamilla Niedzielska, GSK Poznań Site Director said: “We have a talented and dedicated team whose high standards have ensured that the Poznań manufacturing site has been performing strongly. Our priority is to support them through the transition and consult with them along the way, along with Delpharm. In the meantime, we remain wholly committed to maintaining operations and delivering continuity of supply for our patients and consumers.”

Delpharm is committed to expanding its worldwide supply and the Poznań manufacturing site - with its competitive cost base, high quality production, continuous improvement mindset and diverse dose forms - has an important role to play.

Commenting on the sale, Sébastien Aguettant, CEO of Delpharm said: “Further to our existing businesses with GSK Consumer Healthcare and Vaccines, we are delighted to expand our partnership with GSK Pharma with the acquisition of the Poznan sites which is our first step in Central and Eastern Europe.”

GSK has been present in Poland for over 40 years, employing over 2,400 people in the country and striving to improve the health and wellness of people in Poland through the development of innovative medicines, vaccines and consumer healthcare products.

Poznań remains a key strategic location for GSK which has hired over 270 people during the past twelve months at its Europe Finance Hub, established in the city in 2019. The Business Service Centre in Poznań was set up in 2005 and is the biggest GSK unit in Poland, made up of 700 world-class tech specialists, both full time and contract workers.

No other GSK sites in Poland, including the head office in Warsaw, an office site in Poznan and the Logistics and Distribution Centre in Gądki are affected by today’s announcement.

About Delpharm

With more than 900 million units produced per year and 800 million euros of turnover, Delpharm is a worldwide leader in contract development and manufacturing of medicines for pharmaceutical companies. The company operates 17 manufacturing plants (12 in France, 2 in Italy, one in Belgium, one in Canada and one in The Netherlands) providing the majority of dosage forms available on the market: tablets, injectable vials and ampoules, freeze dry, suspensions, solutions, ointments and soft gels.

For more information, please visit our website:

About GSK

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

For further information please visit

Mentioned Companies
View company profile